Hypertension in Hemodialysis Patients (Aim 3)
| Status: | Terminated |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Renal Impairment / Chronic Kidney Disease, Cardiology, Orthopedic |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | August 2005 |
| End Date: | September 2013 |
Hypertension in Hemodialysis Patients
We will directly test the hypothesis that an initial strategy of lisinopril-based therapy
will be more effective than atenolol-based therapy in causing regression of left ventricular
hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar
degree of BP reduction.
will be more effective than atenolol-based therapy in causing regression of left ventricular
hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar
degree of BP reduction.
This is a parallel group, active control, single-center, open-label, randomized controlled
trial comparing the safety and efficacy of initial therapy with an angiotensin converting
enzyme (ACE) inhibitor (lisinopril) vs. beta-blocker therapy (atenolol) each administered
three times weekly after dialysis.
trial comparing the safety and efficacy of initial therapy with an angiotensin converting
enzyme (ACE) inhibitor (lisinopril) vs. beta-blocker therapy (atenolol) each administered
three times weekly after dialysis.
Inclusion Criteria:
1. Patients on chronic hemodialysis for > 3 mos.
2. Compliance with hemodialysis treatments as defined by less than one missed dialysis
per month
3. Hypertension as diagnosed by ambulatory blood pressure monitoring (ABPM) >135/75 mm
Hg after participation in the ultrafiltration (UF) Trial, or those on no
antihypertensive medications but unwilling to do UF Trial.
4. Presence of LVH on echocardiogram defined as left ventricular mass index (LVMi) >104
g/m2 in women and >116 g/m2 in men.
5. Willingness to give informed consent.
Exclusion criteria:
1. Vascular event (stroke, myocardial infarction or limb ischemia requiring bypass)
within previous six months
2. Noncompliance with hemodialysis treatments
3. Known drug abuse
4. Chronic obstructive pulmonary disorder (COPD) requiring home oxygen
5. Congestive Heart Failure Class III or IV.
6. Body mass index > 40 kg/m2.
7. Known contraindication to atenolol (severe heart failure, bradycardia, bronchial
asthma, intolerance or allergy) or lisinopril (cough, pregnancy, intolerance or
allergy)
We found this trial at
1
site
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
Click here to add this to my saved trials
